Information

Dear user, the application need JavaScript support. Please enable JavaScript in your browser.

English (EN)·Polski (PL)·Ukraiński (UK)
Go to the home page of the library Uniwersytet Ekonomiczny we Wrocławiu Link opens in a new window Library logo Prolib Integro - home pageUniwersytet Ekonomiczny we Wrocławiu

You search for a phrase ""Peripheral Blood Stem Cell Transplantation"" according to the criterion: Subject Terms

  Filters
Align
Showing 1-20 from 2182 results
Title:
Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials.
Authors:
Kauer J; Department of Haematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.; Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany.
Freundt EP; Department of Haematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Schmitt A; Department of Haematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Weinhold N; Department of Haematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Mai EK; Department of Haematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.; GMMG Study Group at University Hospital Heidelberg, Heidelberg, Germany.
Müller-Tidow C; Department of Haematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.; Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany.; National Centre for Tumour Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.
Goldschmidt H; Department of Haematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.; GMMG Study Group at University Hospital Heidelberg, Heidelberg, Germany.; National Centre for Tumour Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.
Raab MS; Department of Haematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.; National Centre for Tumour Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.
Kriegsmann K; Department of Haematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.; Laborarztpraxis, Laborarztpraxis Rhein-Main MVZ GbR, Limbach Gruppe SE, Frankfurt Am Main, Germany.
Sauer S; Department of Haematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. .
Show more
Source:
BMC cancer [BMC Cancer] 2023 Nov 21; Vol. 23 (1), pp. 1132. Date of Electronic Publication: 2023 Nov 21.
Publication Type:
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
MeSH Terms:
Heterocyclic Compounds*/therapeutic use
Multiple Myeloma*/drug therapy
Multiple Myeloma*/diagnosis
Peripheral Blood Stem Cell Transplantation*
Humans ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bortezomib/therapeutic use ; Dexamethasone/therapeutic use ; Hematopoietic Stem Cell Mobilization/methods ; Lenalidomide/therapeutic use ; Transplantation, Autologous
Academic Journal
Full Text  Link opens in a new window Full TextDetails
Title:
Safety and efficacy of high-dose cytarabine MEAM therapy and other treatments for auto-peripheral blood stem cell transplantation: A retrospective comparative study.
Authors:
Yui S; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Wakita S; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Nagata Y; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Kuribayashi Y; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Asayama T; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Fujiwara Y; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Sakaguchi M; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Yamanaka S; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Marumo A; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Omori I; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Kinoshita R; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Onai D; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Sunakawa M; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Kaito Y; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Inai K; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Tokura T; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Takeyoshi A; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Yasuda S; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Honma S; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Nakayama K; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Hirakawa T; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Arai K; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Kitano T; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Okamoto M; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Inokuchi K; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Yamaguchi H; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Show more
Source:
Asia-Pacific journal of clinical oncology [Asia Pac J Clin Oncol] 2023 Feb; Vol. 19 (1), pp. 136-148. Date of Electronic Publication: 2022 May 22.
Publication Type:
Journal Article
MeSH Terms:
Peripheral Blood Stem Cell Transplantation*/methods
Hematopoietic Stem Cell Transplantation*/adverse effects
Lymphoma, Large B-Cell, Diffuse*
Humans ; Cytarabine/adverse effects ; Retrospective Studies ; Transplantation, Autologous ; Etoposide/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Melphalan/adverse effects ; Transplantation Conditioning/methods ; Treatment Outcome
Academic Journal
Full Text  Link opens in a new window Full TextDetails
Title:
Immune reconstitution and survival of patients after allogeneic hematopoietic stem cell transplantation from older donors.
Authors:
Jiang P; Department of Hematology, Shanghai Jiao Tong University School of Medicine Affiliated Shanghai General Hospital, Hongkou District, Shanghai, China.
Cai Y; Department of Hematology, Shanghai Jiao Tong University School of Medicine Affiliated Shanghai General Hospital, Hongkou District, Shanghai, China.
Zhou X; Department of Hematology, Shanghai Jiao Tong University School of Medicine Affiliated Shanghai General Hospital, Hongkou District, Shanghai, China.
Yang J; Department of Hematology, Shanghai Jiao Tong University School of Medicine Affiliated Shanghai General Hospital, Hongkou District, Shanghai, China.
Tong Y; Department of Hematology, Shanghai Jiao Tong University School of Medicine Affiliated Shanghai General Hospital, Hongkou District, Shanghai, China.
Huang C; Department of Hematology, Shanghai Jiao Tong University School of Medicine Affiliated Shanghai General Hospital, Hongkou District, Shanghai, China.
Qiu H; Department of Hematology, Shanghai Jiao Tong University School of Medicine Affiliated Shanghai General Hospital, Hongkou District, Shanghai, China.
Zhou K; Department of Hematology, Shanghai Jiao Tong University School of Medicine Affiliated Shanghai General Hospital, Hongkou District, Shanghai, China.
Xu X; Department of Hematology, Shanghai Jiao Tong University School of Medicine Affiliated Shanghai General Hospital, Hongkou District, Shanghai, China.
Zhang Y; Department of Hematology, Shanghai Jiao Tong University School of Medicine Affiliated Shanghai General Hospital, Hongkou District, Shanghai, China.
Niu J; Department of Hematology, Shanghai Jiao Tong University School of Medicine Affiliated Shanghai General Hospital, Hongkou District, Shanghai, China.
Shen C; Department of Hematology, Shanghai Jiao Tong University School of Medicine Affiliated Shanghai General Hospital, Hongkou District, Shanghai, China.
Xia X; Department of Hematology, Shanghai Jiao Tong University School of Medicine Affiliated Shanghai General Hospital, Hongkou District, Shanghai, China.
Wei Y; Department of Hematology, Shanghai Jiao Tong University School of Medicine Affiliated Shanghai General Hospital, Hongkou District, Shanghai, China.
Song X; Department of Hematology, Shanghai Jiao Tong University School of Medicine Affiliated Shanghai General Hospital, Hongkou District, Shanghai, China.
Wan L; Department of Hematology, Shanghai Jiao Tong University School of Medicine Affiliated Shanghai General Hospital, Hongkou District, Shanghai, China.
Show more
Source:
Clinical transplantation [Clin Transplant] 2023 Jan; Vol. 37 (1), pp. e14844. Date of Electronic Publication: 2022 Nov 14.
Publication Type:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Graft vs Host Disease*/etiology
Hematopoietic Stem Cell Transplantation*/adverse effects
Immune Reconstitution*
Peripheral Blood Stem Cell Transplantation*/adverse effects
Aged ; Humans ; Middle Aged ; Neoplasm Recurrence, Local/etiology ; Retrospective Studies
Academic Journal
Full Text  Link opens in a new window Full TextDetails
Title:
Evolution of Graves' Disease during Immune Reconstitution following Nonmyeloablative Haploidentical Peripheral Blood Stem Cell Transplantation in a Boy Carrying Germline SAMD9L and FLT3 Variants.
Authors:
Ip PP; Institute of Molecular Biology, Academia Sinica, Taipei City 115, Taiwan.
Fang LH; Department of Pharmacy, Koo Foundation Sun Yat-Sen Cancer Center, Taipei City 112, Taiwan.
Shen YL; Institute of Molecular Biology, Academia Sinica, Taipei City 115, Taiwan.
Tung KC; Institute of Molecular Biology, Academia Sinica, Taipei City 115, Taiwan.
Lai MT; Taiwan Genome Industry Alliance Inc., Taipei City 115, Taiwan.
Juan LY; Division of Endocrinology, Department of Internal Medicine, Koo Foundation Sun Yat-Sen Cancer Center, Taipei City 112, Taiwan.
Chen LY; Institute of Molecular Biology, Academia Sinica, Taipei City 115, Taiwan.
Chen RL; Department of Pediatric Hematology and Oncology, Koo Foundation Sun Yat-Sen Cancer Center, Taipei City 112, Taiwan.
Show more
Source:
International journal of molecular sciences [Int J Mol Sci] 2022 Aug 22; Vol. 23 (16). Date of Electronic Publication: 2022 Aug 22.
Publication Type:
Case Reports
MeSH Terms:
Graft vs Host Disease*/genetics
Graves Disease*/genetics
Graves Disease*/therapy
Hematopoietic Stem Cell Transplantation*/methods
Immune Reconstitution*
Peripheral Blood Stem Cell Transplantation*
Germ Cells ; Humans ; Male ; fms-Like Tyrosine Kinase 3
Report
Full Text  Link opens in a new window Full TextDetails
Title:
A pyruvate kinase deficiency child with novel PK-LR gene mutations was successfully cured by matched unrelated donor peripheral blood stem cell transplantation.
Authors:
Zhan LP; Department of Pediatrics, Sun Yat-sen Memorial Hospital, SunYat-sen University, Guangzhou, China.; Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes, Sun Yat-sen University, Guangzhou, China.
Que LP; Department of Pediatrics, Sun Yat-sen Memorial Hospital, SunYat-sen University, Guangzhou, China.; Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes, Sun Yat-sen University, Guangzhou, China.
Wu ZZ; Department of Pediatrics, Sun Yat-sen Memorial Hospital, SunYat-sen University, Guangzhou, China.; Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes, Sun Yat-sen University, Guangzhou, China.
Liu DD; Department of Pediatrics, Sun Yat-sen Memorial Hospital, SunYat-sen University, Guangzhou, China.; Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes, Sun Yat-sen University, Guangzhou, China.
Wang KM; Department of Pediatrics, Sun Yat-sen Memorial Hospital, SunYat-sen University, Guangzhou, China.; Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes, Sun Yat-sen University, Guangzhou, China.
Xu HG; Department of Pediatrics, Sun Yat-sen Memorial Hospital, SunYat-sen University, Guangzhou, China.; Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes, Sun Yat-sen University, Guangzhou, China.
Fang JP; Department of Pediatrics, Sun Yat-sen Memorial Hospital, SunYat-sen University, Guangzhou, China.; Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes, Sun Yat-sen University, Guangzhou, China.
Huang K; Department of Pediatrics, Sun Yat-sen Memorial Hospital, SunYat-sen University, Guangzhou, China.; Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes, Sun Yat-sen University, Guangzhou, China.
Show more
Source:
Pediatric transplantation [Pediatr Transplant] 2021 Nov; Vol. 25 (7), pp. e14078. Date of Electronic Publication: 2021 Jul 13.
Publication Type:
Case Reports; Journal Article
MeSH Terms:
Peripheral Blood Stem Cell Transplantation*
Anemia, Hemolytic, Congenital Nonspherocytic/*therapy
Pyruvate Kinase/*deficiency
Pyruvate Kinase/*genetics
Pyruvate Metabolism, Inborn Errors/*therapy
Child, Preschool ; Humans ; Male ; Mutation ; Unrelated Donors
SCR Disease Name:
Pyruvate Kinase Deficiency of Red Cells
Academic Journal
Full Text  Link opens in a new window Full TextDetails
Title:
Assessment of the association between cytomegalovirus DNAemia and subsequent acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation: A multicenter study from the Spanish hematopoietic transplantation and cell therapy group.
Authors:
Bueno F; Microbiology Service, Hospital Clínico Universitario, INCLIVA Research Institute, Valencia, Spain.
Solano C; Hematology Department, Hospital Clínico Universitario, INCLIVA Research Institute, Valencia, Spain.; Department of Medicine, School of Medicine, University of Valencia, Valencia, Spain.
Vázquez L; Hematology Department, Complejo Asistencial Universitario de Salamanca-IBSAL, Salamanca, Spain.
Giménez E; Microbiology Service, Hospital Clínico Universitario, INCLIVA Research Institute, Valencia, Spain.
de la Cámara R; Hematology Department, Hospital de la Princesa, Madrid, Spain.
Albert E; Microbiology Service, Hospital Clínico Universitario, INCLIVA Research Institute, Valencia, Spain.
Rovira M; Hematology Department, Hospital Clinic Institute of Hematology & Oncology, Barcelona, Spain.
Espigado I; Hematology Department, Hospital Virgen del Rocío, Sevilla, Spain.
Martín Calvo C; Hematology Department, Hospital Universitario Reina Sofía, Córdoba, Spain.
López-Jiménez J; Hematology Department, Hospital Ramón y Cajal, Madrid, Spain.
Suárez-Lledó M; Hematology Department, Hospital Clinic Institute of Hematology & Oncology, Barcelona, Spain.
Chinea A; Hematology Department, Hospital Ramón y Cajal, Madrid, Spain.
Esquirol A; Hematology Department, Hospital Sant Creu i Sant Pau, Barcelona, Spain.
Pérez A; Hematology Department, Hospital Clínico Universitario, INCLIVA Research Institute, Valencia, Spain.
Bermúdez A; Department of Hematology, Hospital Marques de Valdecilla, Santander, Spain.
Saldaña R; Hematology Department, Hospital Universitario de Jerez, Spain.
Heras I; Hematology Department, Hospital Universitario Morales Meseguer y Centro Regional de Hemodonación, IMIB, Universidad de Murcia, Spain.
González-Huerta AJ; Hematology-Stem cell Transplantation Unit, Hospital Universitario Central de Asturias, Oviedo IISPA. IUOPA, Oviedo, Spain.
Torrado T; Hematology Department, Complejo Hospitalario Universitario, Vigo, Spain.
Batlle M; Hematology Department, Hospital Germans Trias i Pujol, Barcelona, Spain.
Jiménez S; Hematology Department, Hospital Universitario Doctor Negrín de Gran Canaria, Las Palmas, Spain.
Vallejo C; Hematology Department, Hospital Universitario Donostia-Aránzazu, San Sebastián, Spain.
Barba P; Hematology Department Hospital, Universitario Vall de Hebrón, Barcelona, Spain.
Cuesta MÁ; Hematology Department, Hospital Regional Universitario, Málaga, Spain.
Duarte R; Hematology Department, Hospital Puerta de Hierro, Madrid, Spain.
Piñana JL; Hematology Department, Hospital Clínico Universitario, INCLIVA Research Institute, Valencia, Spain.; Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.; CIBERONC, Instituto Carlos III, Madrid, Spain.
Navarro D; Microbiology Service, Hospital Clínico Universitario, INCLIVA Research Institute, Valencia, Spain.; Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain.
Show more
Corporate Authors:
Spanish Group of Hematopoietic Transplantation, Cell Therapy (GETH)
Source:
Transplant infectious disease : an official journal of the Transplantation Society [Transpl Infect Dis] 2021 Aug; Vol. 23 (4), pp. e13627. Date of Electronic Publication: 2021 May 18.
Publication Type:
Journal Article; Multicenter Study; Observational Study
MeSH Terms:
Graft vs Host Disease*
Hematopoietic Stem Cell Transplantation*/adverse effects
Peripheral Blood Stem Cell Transplantation*
Cytomegalovirus/genetics ; Humans ; Retrospective Studies
Academic Journal
Full Text  Link opens in a new window Full TextDetails
Title:
Grade 3-4 cytokine release syndrome is associated with poor survival in haploidentical peripheral blood stem cell transplantation.
Authors:
Modi D; Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
Albanyan O; Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
Kim S; Department of Oncology, Biostatistics Core, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
Deol A; Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
Ayash L; Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
Ratanatharathorn V; Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
Uberti JP; Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
Show more
Source:
Leukemia & lymphoma [Leuk Lymphoma] 2021 Aug; Vol. 62 (8), pp. 1982-1989. Date of Electronic Publication: 2021 Feb 24.
Publication Type:
Journal Article
MeSH Terms:
Graft vs Host Disease*/etiology
Hematopoietic Stem Cell Transplantation*
Peripheral Blood Stem Cell Transplantation*/adverse effects
Cyclophosphamide ; Cytokine Release Syndrome ; Humans ; Neoplasm Recurrence, Local ; Retrospective Studies ; Transplantation Conditioning/adverse effects
Academic Journal
Full Text  Link opens in a new windowDetails
Title:
Feasibility of reduced-dose posttransplant cyclophosphamide and cotransplantation of peripheral blood stem cells and umbilical cord-derived mesenchymal stem cells for SAA.
Authors:
Zu Y; Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, 450000, People's Republic of China.
Zhou J; Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, 450000, People's Republic of China. .
Fu Y; Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, 450000, People's Republic of China.
Fang B; Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, 450000, People's Republic of China.
Liu X; Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, 450000, People's Republic of China.
Zhang Y; Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, 450000, People's Republic of China.
Yu F; Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, 450000, People's Republic of China.
Zuo W; Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, 450000, People's Republic of China.
Zhou H; Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, 450000, People's Republic of China.
Gui R; Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, 450000, People's Republic of China.
Li Z; Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, 450000, People's Republic of China.
Liu Y; Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, 450000, People's Republic of China.
Zhao H; Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, 450000, People's Republic of China.
Zhang C; Center of Bio-Repository, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, 450000, People's Republic of China.
Song Y; Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, 450000, People's Republic of China. .
Show more
Source:
Scientific reports [Sci Rep] 2021 Jan 08; Vol. 11 (1), pp. 253. Date of Electronic Publication: 2021 Jan 08.
Publication Type:
Journal Article; Randomized Controlled Trial
MeSH Terms:
Anemia, Aplastic/*therapy
Cyclophosphamide/*administration & dosage
Graft vs Host Disease/*prevention & control
Mesenchymal Stem Cell Transplantation/*methods
Peripheral Blood Stem Cell Transplantation/*methods
Transplantation Conditioning/*methods
Adolescent ; Adult ; Anemia, Aplastic/mortality ; Child ; Cyclophosphamide/adverse effects ; Feasibility Studies ; Female ; Graft vs Host Disease/mortality ; Humans ; Kaplan-Meier Estimate ; Male ; Mesenchymal Stem Cell Transplantation/adverse effects ; Mesenchymal Stem Cell Transplantation/mortality ; Off-Label Use ; Peripheral Blood Stem Cell Transplantation/adverse effects ; Peripheral Blood Stem Cell Transplantation/mortality ; Siblings ; Tissue Donors ; Transplantation, Haploidentical/methods ; Treatment Outcome ; Umbilical Cord/cytology ; Young Adult
Academic Journal
Full Text  Link opens in a new window Full TextDetails
Title:
Can planned CD34+ stem cell boost prevent poor graft function after peripheral blood haploidentical hematopoietic transplantation?
Authors:
Abboud R; Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA.
Slade M; Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA.
Abboud C; Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA.
DiPersio JF; Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA.
Show more
Source:
Leukemia & lymphoma [Leuk Lymphoma] 2021 Mar; Vol. 62 (3), pp. 749-751. Date of Electronic Publication: 2020 Nov 02.
Publication Type:
Letter; Research Support, Non-U.S. Gov't
MeSH Terms:
Graft vs Host Disease*/etiology
Graft vs Host Disease*/prevention & control
Hematopoietic Stem Cell Transplantation*/adverse effects
Peripheral Blood Stem Cell Transplantation*/adverse effects
Antigens, CD34 ; Humans ; Transplantation Conditioning ; Transplantation, Haploidentical ; Transplantation, Homologous
Report
Full Text  Link opens in a new windowDetails
Title:
G-CSF use post peripheral blood stem cell transplant is associated with faster neutrophil engraftment, shorter hospital stay and increased incidence of chronic GVHD.
Authors:
Singh V; Department of Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, MI, USA.
Jang H; Biostatistics Core, Karmanos Cancer Institute, Department of Oncology, Wayne State University, Detroit, MI, USA.
Kim S; Biostatistics Core, Karmanos Cancer Institute, Department of Oncology, Wayne State University, Detroit, MI, USA.
Ayash L; Department of Oncology, Blood and Marrow Stem Cell Transplant Program, Karmanos Cancer Institute/Wayne State University, Detroit, MI, USA.
Alavi A; Department of Oncology, Blood and Marrow Stem Cell Transplant Program, Karmanos Cancer Institute/Wayne State University, Detroit, MI, USA.
Ratanatharathorn V; Department of Oncology, Blood and Marrow Stem Cell Transplant Program, Karmanos Cancer Institute/Wayne State University, Detroit, MI, USA.
Uberti JP; Department of Oncology, Co-Director, Blood and Marrow Stem Cell Transplant Program, Karmanos Cancer Institute/Wayne State University, Detroit, MI, USA.
Deol A; Department of Oncology, Blood and Marrow Stem Cell Transplant Program, Karmanos Cancer Institute/Wayne State University, Detroit, MI, USA.
Show more
Source:
Leukemia & lymphoma [Leuk Lymphoma] 2021 Feb; Vol. 62 (2), pp. 446-453. Date of Electronic Publication: 2020 Oct 12.
Publication Type:
Journal Article
MeSH Terms:
Graft vs Host Disease*/epidemiology
Graft vs Host Disease*/etiology
Hematopoietic Stem Cell Transplantation*/adverse effects
Peripheral Blood Stem Cell Transplantation*/adverse effects
Bone Marrow Transplantation ; Granulocyte Colony-Stimulating Factor ; Hospitals ; Humans ; Incidence ; Length of Stay ; Neutrophils ; Transplantation, Homologous
Academic Journal
Full Text  Link opens in a new window Full TextDetails
Title:
A study to compare Hematopoietic Progenitor Cell count determined on a next-generation automated cell counter with flow cytometric CD34 count in peripheral blood and the harvested peripheral blood stem cell graft from autologous and allogenic donors.
Authors:
Mishra S; Department of Transfusion Medicine and Immuno-haematology, Vellore, India.
Kulkarni U; Department of Haematology, Christian Medical College and Hospital, Vellore, India.
Mathews N; Department of Transfusion Medicine and Immuno-haematology, Vellore, India.
V R; Department of Transfusion Medicine and Immuno-haematology, Vellore, India.
Ch Nair S; Department of Transfusion Medicine and Immuno-haematology, Vellore, India.
George B; Department of Haematology, Christian Medical College and Hospital, Vellore, India.
Mammen JJ; Department of Transfusion Medicine and Immuno-haematology, Vellore, India.
Show more
Source:
International journal of laboratory hematology [Int J Lab Hematol] 2021 Feb; Vol. 43 (1), pp. 76-83. Date of Electronic Publication: 2020 Sep 14.
Publication Type:
Clinical Trial; Comparative Study; Journal Article
MeSH Terms:
Flow Cytometry*
Hematologic Diseases*/blood
Hematologic Diseases*/therapy
Peripheral Blood Stem Cell Transplantation*
Tissue Donors*
Hematopoietic Stem Cells/*metabolism
Adolescent ; Adult ; Aged ; Allografts ; Autografts ; Child ; Child, Preschool ; Female ; Humans ; Male ; Middle Aged
Academic Journal
Full Text  Link opens in a new window Full TextDetails
Title:
Absolute lymphocyte count on the first day of thymoglobulin predicts relapse-free survival in matched unrelated peripheral blood stem cell transplantation.
Authors:
Modi D; Department of Oncology, Blood and Marrow Stem Cell Transplant Program, Karmanos Cancer Institute/Wayne State University, Detroit, MI, USA.
Kim S; Biostatistics Core, Karmanos Cancer Institute, Department of Oncology, Wayne State University, Detroit, MI, USA.
Surapaneni M; Department of Oncology, Blood and Marrow Stem Cell Transplant Program, Karmanos Cancer Institute/Wayne State University, Detroit, MI, USA.
Ayash L; Department of Oncology, Blood and Marrow Stem Cell Transplant Program, Karmanos Cancer Institute/Wayne State University, Detroit, MI, USA.
Ratanatharathorn V; Department of Oncology, Blood and Marrow Stem Cell Transplant Program, Karmanos Cancer Institute/Wayne State University, Detroit, MI, USA.
Uberti JP; Department of Oncology, Co-Director, Blood & Marrow Stem Cell Transplant Program, Karmanos Cancer Institute/Wayne State University, Detroit, MI, USA.
Deol A; Biostatistics Core, Karmanos Cancer Institute, Department of Oncology, Wayne State University, Detroit, MI, USA.
Show more
Source:
Leukemia & lymphoma [Leuk Lymphoma] 2020 Dec; Vol. 61 (13), pp. 3137-3145. Date of Electronic Publication: 2020 Aug 11.
Publication Type:
Journal Article
MeSH Terms:
Graft vs Host Disease*
Hematopoietic Stem Cell Transplantation*
Peripheral Blood Stem Cell Transplantation*
Antilymphocyte Serum ; Humans ; Lymphocyte Count ; Recurrence ; Retrospective Studies ; Transplantation Conditioning ; Unrelated Donors
Academic Journal
Full Text  Link opens in a new window Full TextDetails
Title:
Autologous stem cell transplantation in peripheral T-cell lymphoma: better mobilization of blood CD34 cells is associated with improved survival.
Authors:
Partanen A; Department of Medicine, Kuopio University Hospital, Kuopio, Finland.
Turunen A; Department of Medicine, Kuopio University Hospital, Kuopio, Finland.; Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
Valtola J; Department of Medicine, Kuopio University Hospital, Kuopio, Finland.
Pyörälä M; Department of Medicine, Kuopio University Hospital, Kuopio, Finland.
Vasala K; Department of Oncology, Central Hospital of Central Finland, Jyväskylä, Finland.
Kuittinen O; Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.; Department of Oncology, Oulu University Hospital, Oulu, Finland.; Department of Oncology, Kuopio University Hospital, Kuopio, Finland.
Kuitunen H; Department of Oncology, Oulu University Hospital, Oulu, Finland.
Penttilä K; Department of Medicine, Central Hospital of Savonlinna, Savonlinna, Finland.; Finnish Medicines Agency, Kuopio, Finland.
Kuittinen T; Department of Medicine, Kuopio University Hospital, Kuopio, Finland.
Mäntymaa P; Eastern Finland Laboratory Centre, Kuopio, Finland.
Pelkonen J; Eastern Finland Laboratory Centre, Kuopio, Finland.; Department of Clinical Microbiology, University of Eastern Finland, Kuopio, Finland.
Varmavuo V; Department of Medicine, Kymenlaakso Central Hospital, Kotka, Finland.
Jantunen E; Department of Medicine, Kuopio University Hospital, Kuopio, Finland.; Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.; Siunsote-Department of Medicine, Hospital District of North Karelia, Joensuu, Finland.
Show more
Source:
Leukemia & lymphoma [Leuk Lymphoma] 2020 Dec; Vol. 61 (12), pp. 3027-3029. Date of Electronic Publication: 2020 Jul 10.
Publication Type:
Letter
MeSH Terms:
Hematopoietic Stem Cell Transplantation*
Lymphoma, T-Cell, Peripheral*/therapy
Peripheral Blood Stem Cell Transplantation*
Antigens, CD34 ; Granulocyte Colony-Stimulating Factor ; Hematopoietic Stem Cell Mobilization ; Humans ; Transplantation, Autologous
Editorial & Opinion
Full Text  Link opens in a new window Full TextDetails
Title:
Complications for a Hoyeraal-Hreidarsson Syndrome Patient with a Germline DKC1 A353V Variant Undergoing Unrelated Peripheral Blood Stem Cell Transplantation.
Authors:
Chen RL; Department of Pediatric Hematology and Oncology, Koo Foundation Sun Yat-Sen Cancer Center, Taipei 11259, Taiwan. .
Lin KK; Institute of Molecular Biology, Academia Sinica, Taipei 11529, Taiwan.
Chen LY; Institute of Molecular Biology, Academia Sinica, Taipei 11529, Taiwan. .
Show more
Source:
International journal of molecular sciences [Int J Mol Sci] 2019 Jul 02; Vol. 20 (13). Date of Electronic Publication: 2019 Jul 02.
Publication Type:
Case Reports
MeSH Terms:
Peripheral Blood Stem Cell Transplantation*/adverse effects
Peripheral Blood Stem Cell Transplantation*/methods
Cell Cycle Proteins/*genetics
Dyskeratosis Congenita/*therapy
Fetal Growth Retardation/*therapy
Intellectual Disability/*therapy
Microcephaly/*therapy
Nuclear Proteins/*genetics
Child, Preschool ; Dyskeratosis Congenita/complications ; Dyskeratosis Congenita/genetics ; Dyskeratosis Congenita/pathology ; Fetal Growth Retardation/genetics ; Fetal Growth Retardation/pathology ; Humans ; Intellectual Disability/complications ; Intellectual Disability/genetics ; Intellectual Disability/pathology ; Male ; Microcephaly/complications ; Microcephaly/genetics ; Microcephaly/pathology ; Point Mutation
SCR Disease Name:
Hoyeraal Hreidarsson syndrome
Report
Full Text  Link opens in a new window Full TextDetails
Title:
Safety and efficacy of four cycles of Brentuximab Vedotin as consolidation after autologous peripheral stem cell transplantation in relapsed/refractory Hodgkin lymphoma.
Authors:
Kort J; Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Chidiac A; Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
El Sayed R; Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Massoud R; Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Nehme R; Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Bazarbachi A; Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
El-Cheikh J; Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Show more
Source:
Leukemia & lymphoma [Leuk Lymphoma] 2020 Jul; Vol. 61 (7), pp. 1732-1735. Date of Electronic Publication: 2020 Feb 22.
Publication Type:
Letter
MeSH Terms:
Hematopoietic Stem Cell Transplantation*
Hodgkin Disease*/drug therapy
Immunoconjugates*
Peripheral Blood Stem Cell Transplantation*
Adult ; Brentuximab Vedotin ; Humans ; Neoplasm Recurrence, Local ; Salvage Therapy ; Stem Cell Transplantation ; Transplantation, Autologous
Editorial & Opinion
Full Text  Link opens in a new window Full TextDetails
Title:
Autologous stem cell transplantation is safe in selected elderly multiple myeloma patients.
Authors:
Antonioli E; Haematology Unit, Careggi University Hospital, Florence, Italy.
Nozzoli C; Cellular Therapy and Transfusion Medicine Unit, Careggi University Hospital, Florence, Italy.
Buda G; Department of Clinical and Experimental Medicine, U.O. Hematology, University of Pisa, Pisa, Italy.
Staderini M; Haematology Unit, Careggi University Hospital, Florence, Italy.
Boncompagni R; Cellular Therapy and Transfusion Medicine Unit, Careggi University Hospital, Florence, Italy.
Martini F; Department of Clinical and Experimental Medicine, U.O. Hematology, University of Pisa, Pisa, Italy.
Petrini M; Department of Clinical and Experimental Medicine, U.O. Hematology, University of Pisa, Pisa, Italy.
Bosi A; Haematology Unit, Careggi University Hospital, Florence, Italy.
Saccardi R; Cellular Therapy and Transfusion Medicine Unit, Careggi University Hospital, Florence, Italy.
Show more
Source:
European journal of haematology [Eur J Haematol] 2020 Feb; Vol. 104 (2), pp. 138-144. Date of Electronic Publication: 2019 Dec 12.
Publication Type:
Clinical Trial; Journal Article
MeSH Terms:
Peripheral Blood Stem Cell Transplantation*
Bortezomib/*administration & dosage
Multiple Myeloma/*therapy
Aged ; Autografts ; Cyclophosphamide/administration & dosage ; Disease-Free Survival ; Female ; Granulocyte Colony-Stimulating Factor/administration & dosage ; Humans ; Induction Chemotherapy ; Male ; Multiple Myeloma/mortality ; Retrospective Studies ; Survival Rate
Academic Journal
Full Text  Link opens in a new window Full TextDetails
Title:
Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide.
Authors:
Mariotti J; Bone Marrow Transplant Unit, Humanitas Clinical and Research Center-IRCCS-via Manzoni 56, Rozzano, Italy.
Taurino D; Bone Marrow Transplant Unit, Humanitas Clinical and Research Center-IRCCS-via Manzoni 56, Rozzano, Italy.
Marino F; Bone Marrow Transplant Unit, Humanitas Clinical and Research Center-IRCCS-via Manzoni 56, Rozzano, Italy.
Bramanti S; Bone Marrow Transplant Unit, Humanitas Clinical and Research Center-IRCCS-via Manzoni 56, Rozzano, Italy.
Sarina B; Bone Marrow Transplant Unit, Humanitas Clinical and Research Center-IRCCS-via Manzoni 56, Rozzano, Italy.
Morabito L; Bone Marrow Transplant Unit, Humanitas Clinical and Research Center-IRCCS-via Manzoni 56, Rozzano, Italy.
De Philippis C; Bone Marrow Transplant Unit, Humanitas Clinical and Research Center-IRCCS-via Manzoni 56, Rozzano, Italy.
Di Vito C; Unit of Clinical and Experimental Immunology, Humanitas Clinical and Research Center, Rozzano, Italy.
Mavilio D; Unit of Clinical and Experimental Immunology, Humanitas Clinical and Research Center, Rozzano, Italy.
Carlo-Stella C; Bone Marrow Transplant Unit, Humanitas Clinical and Research Center-IRCCS-via Manzoni 56, Rozzano, Italy.; Department of Medical Biotechnology and Translational Medicine, University of Milano, Milano, Italy.
Della Porta M; Bone Marrow Transplant Unit, Humanitas Clinical and Research Center-IRCCS-via Manzoni 56, Rozzano, Italy.
Santoro A; Bone Marrow Transplant Unit, Humanitas Clinical and Research Center-IRCCS-via Manzoni 56, Rozzano, Italy.; Humanitas Clinical and Research Hospital, Humanitas University, Rozzano, Italy.
Castagna L; Bone Marrow Transplant Unit, Humanitas Clinical and Research Center-IRCCS-via Manzoni 56, Rozzano, Italy.
Show more
Source:
Cancer medicine [Cancer Med] 2020 Jan; Vol. 9 (1), pp. 52-61. Date of Electronic Publication: 2019 Nov 08.
Publication Type:
Journal Article
MeSH Terms:
Bone Marrow Transplantation/*adverse effects
Cytokine Release Syndrome/*epidemiology
HLA-DRB1 Chains/*immunology
Hematologic Neoplasms/*therapy
Peripheral Blood Stem Cell Transplantation/*adverse effects
Adolescent ; Adult ; Aged ; Bone Marrow Transplantation/methods ; Cyclophosphamide/administration & dosage ; Cytokine Release Syndrome/diagnosis ; Cytokine Release Syndrome/immunology ; Female ; Graft vs Host Disease/epidemiology ; Graft vs Host Disease/immunology ; Graft vs Host Disease/prevention & control ; HLA-DRB1 Chains/analysis ; Hematologic Neoplasms/diagnosis ; Hematologic Neoplasms/immunology ; Histocompatibility Testing ; Humans ; Immunosuppressive Agents/administration & dosage ; Incidence ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Peripheral Blood Stem Cell Transplantation/methods ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Severity of Illness Index ; Transplantation Conditioning/methods ; Transplantation, Haploidentical/adverse effects ; Transplantation, Haploidentical/methods ; Young Adult
Academic Journal
Full Text  Link opens in a new window Full TextDetails
Title:
Unmanipulated haploidentical peripheral blood stem cell transplantation for patients with Philadelphia-negative acute lymphoblastic leukaemia in first complete remission.
Authors:
Wang F; Medical School, Nankai University, Tianjin, China.; Department of Hematology, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
Liu T; Inpatient Department, 66242 Army Hospital, Xilin Gol, China.
Wang L; Department of Hematology and Oncology, Chinese PLA 401 Hospital, Qingdao, China.
Gu Z; Department of Hematology, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
Yang N; Department of Hematology, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
Luo L; Department of Hematology, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
Zhu C; Medical School, Nankai University, Tianjin, China.; Department of Hematology, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
Li M; Department of Hematology, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
Liu D; Department of Hematology, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
Gao C; Medical School, Nankai University, Tianjin, China.; Department of Hematology, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
Show more
Source:
Leukemia & lymphoma [Leuk Lymphoma] 2020 Jan; Vol. 61 (1), pp. 118-127. Date of Electronic Publication: 2019 Sep 13.
Publication Type:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Graft vs Host Disease*
Hematopoietic Stem Cell Transplantation*/adverse effects
Peripheral Blood Stem Cell Transplantation*/adverse effects
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/diagnosis
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/therapy
Humans ; Retrospective Studies ; Transplantation Conditioning ; Treatment Outcome
Academic Journal
Full Text  Link opens in a new window Full TextDetails
Title:
Impact of lenalidomide on collected hematopoietic myeloid and erythroid progenitors: peripheral stem cell collection may not be affected.
Authors:
Dosani T; Internal Medicine Department, University Hospitals Seidman Cancer Center , Cleveland , OH , USA.
Covut F; Stem Cell Transplant Program University Hospitals Seidman Cancer Center Case Comprehensive Cancer Center and Case Western Reserve University , Cleveland , OH , USA.
Pinto R; Stem Cell Transplant Program University Hospitals Seidman Cancer Center Case Comprehensive Cancer Center and Case Western Reserve University , Cleveland , OH , USA.
Kim BG; Pediatrics & Angie Fowler AYA Cancer Institute Case Western Reserve University , Cleveland , OH , USA.
Ali N; Stem Cell Transplant Program University Hospitals Seidman Cancer Center Case Comprehensive Cancer Center and Case Western Reserve University , Cleveland , OH , USA.
Beck R; Pathology Department, University Hospitals Cleveland Medical Center , Cleveland , OH , USA.
Maitta R; Pathology Department, University Hospitals Cleveland Medical Center , Cleveland , OH , USA.
Downes K; Pathology Department, University Hospitals Cleveland Medical Center , Cleveland , OH , USA.
Fox R; Cellular Therapy Lab Case Western Reserve University , Cleveland , OH , USA.
Reese J; Cellular Therapy Lab Case Western Reserve University , Cleveland , OH , USA.
de Lima M; Stem Cell Transplant Program University Hospitals Seidman Cancer Center Case Comprehensive Cancer Center and Case Western Reserve University , Cleveland , OH , USA.
Malek E; Stem Cell Transplant Program University Hospitals Seidman Cancer Center Case Comprehensive Cancer Center and Case Western Reserve University , Cleveland , OH , USA.
Show more
Source:
Leukemia & lymphoma [Leuk Lymphoma] 2019 Sep; Vol. 60 (9), pp. 2199-2206. Date of Electronic Publication: 2019 Mar 07.
Publication Type:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Peripheral Blood Stem Cell Transplantation*
Hematopoietic Stem Cell Mobilization/*adverse effects
Lenalidomide/*adverse effects
Leukapheresis/*statistics & numerical data
Multiple Myeloma/*therapy
Adult ; Aged ; Autografts/drug effects ; Benzylamines ; Chemotherapy, Adjuvant/adverse effects ; Chemotherapy, Adjuvant/methods ; Cyclams ; Female ; Hematopoietic Stem Cell Mobilization/methods ; Heterocyclic Compounds/administration & dosage ; Heterocyclic Compounds/adverse effects ; Humans ; Induction Chemotherapy/adverse effects ; Induction Chemotherapy/methods ; Lenalidomide/administration & dosage ; Male ; Middle Aged ; Multiple Myeloma/blood ; Multiple Myeloma/immunology ; Neoadjuvant Therapy/adverse effects ; Neoadjuvant Therapy/methods ; Regression Analysis ; Retrospective Studies ; Transplantation, Autologous ; Treatment Outcome
Academic Journal
Full Text  Link opens in a new window Full TextDetails
Title:
Systemic administration of quality- and quantity-controlled PBMNCs reduces bisphosphonate-related osteonecrosis of jaw-like lesions in mice.
Authors:
Kuroshima S; Department of Applied Prosthodontics, Institute of Biomedical Sciences, Nagasaki University, 1-7-1, Sakamoto, Nagasaki, 852-8588, Japan. .
Nakajima K; Department of Applied Prosthodontics, Institute of Biomedical Sciences, Nagasaki University, 1-7-1, Sakamoto, Nagasaki, 852-8588, Japan.
Sasaki M; Department of Applied Prosthodontics, Institute of Biomedical Sciences, Nagasaki University, 1-7-1, Sakamoto, Nagasaki, 852-8588, Japan.
I T; Department of Regenerative Oral Surgery, Institute of Biomedical Sciences, Nagasaki University, 1-7-1, Sakamoto, Nagasaki, 852-8588, Japan.
Sumita Y; Basic and Translational Research Center for Hard Tissue Disease, Institute of Biomedical Sciences, Nagasaki University, 1-7-1, Sakamoto, Nagasaki, 852-8588, Japan.
Asahara T; Department of Regenerative Medicine Science, Tokai University School of Medicine, 143, Shimokasuya, Isehara, 259-1193, Japan.
Asahina I; Department of Regenerative Oral Surgery, Institute of Biomedical Sciences, Nagasaki University, 1-7-1, Sakamoto, Nagasaki, 852-8588, Japan.
Sawase T; Department of Applied Prosthodontics, Institute of Biomedical Sciences, Nagasaki University, 1-7-1, Sakamoto, Nagasaki, 852-8588, Japan.
Show more
Source:
Stem cell research & therapy [Stem Cell Res Ther] 2019 Jul 16; Vol. 10 (1), pp. 209. Date of Electronic Publication: 2019 Jul 16.
Publication Type:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Peripheral Blood Stem Cell Transplantation*
Wound Healing*
Bisphosphonate-Associated Osteonecrosis of the Jaw/*therapy
Macrophages/*transplantation
Animals ; Bisphosphonate-Associated Osteonecrosis of the Jaw/diagnostic imaging ; Bisphosphonate-Associated Osteonecrosis of the Jaw/etiology ; Bisphosphonate-Associated Osteonecrosis of the Jaw/physiopathology ; Cyclophosphamide/toxicity ; Disease Models, Animal ; Humans ; Leukocytes, Mononuclear/transplantation ; Mice ; Molar/diagnostic imaging ; Molar/drug effects ; Molar/growth & development ; Tooth Extraction ; X-Ray Microtomography ; Zoledronic Acid/toxicity
Academic Journal
Full Text  Link opens in a new window Full TextDetails
Showing 1-20 from 2182 results

We use cookies to help identify your computer so we can tailor your user experience, track shopping basket contents and remember where you are in the order process.